- Home
- XPON vs ENSC Comparison
XPON vs ENSC Comparison
Compare XPON & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- ENSC
- Stock Information
- Founded
- XPON 2016
- ENSC 2003
- Country
- XPON United States
- ENSC United States
- Employees
- XPON N/A
- ENSC N/A
- Industry
- XPON Electronic Components
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- XPON Technology
- ENSC Health Care
- Exchange
- XPON Nasdaq
- ENSC Nasdaq
- Market Cap
- XPON 6.2M
- ENSC 6.4M
- IPO Year
- XPON 2022
- ENSC N/A
- Fundamental
- Price
- XPON $1.21
- ENSC $2.06
- Analyst Decision
- XPON
- ENSC
- Analyst Count
- XPON 0
- ENSC 0
- Target Price
- XPON N/A
- ENSC N/A
- AVG Volume (30 Days)
- XPON 2.0M
- ENSC 71.2K
- Earning Date
- XPON 11-13-2025
- ENSC 11-14-2025
- Dividend Yield
- XPON N/A
- ENSC N/A
- EPS Growth
- XPON N/A
- ENSC N/A
- EPS
- XPON N/A
- ENSC N/A
- Revenue
- XPON $9,417,947.00
- ENSC $4,487,973.00
- Revenue This Year
- XPON $61.26
- ENSC N/A
- Revenue Next Year
- XPON N/A
- ENSC N/A
- P/E Ratio
- XPON N/A
- ENSC N/A
- Revenue Growth
- XPON 109.37
- ENSC 1.51
- 52 Week Low
- XPON $0.60
- ENSC $1.62
- 52 Week High
- XPON $5.50
- ENSC $11.13
- Technical
- Relative Strength Index (RSI)
- XPON 40.65
- ENSC 41.40
- Support Level
- XPON $1.11
- ENSC $2.02
- Resistance Level
- XPON $1.32
- ENSC $2.17
- Average True Range (ATR)
- XPON 0.11
- ENSC 0.11
- MACD
- XPON -0.00
- ENSC -0.01
- Stochastic Oscillator
- XPON 18.32
- ENSC 35.71
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.